Citius Pharmaceuticals Inc (NASDAQ:CTXR) was down 21.3% during mid-day trading on Thursday . The stock traded as low as $0.42 and last traded at $0.48, approximately 585,851 shares were traded during mid-day trading. An increase of 263% from the average daily volume of 161,466 shares. The stock had previously closed at $0.61.
Several equities analysts have issued reports on CTXR shares. Zacks Investment Research lowered shares of Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, October 7th. Dawson James began coverage on shares of Citius Pharmaceuticals in a report on Friday, September 6th. They issued a “buy” rating and a $7.00 price target on the stock.
The company’s 50 day moving average price is $0.92 and its 200 day moving average price is $1.09. The firm has a market capitalization of $13.47 million, a price-to-earnings ratio of -0.52 and a beta of 0.62.
Citius Pharmaceuticals (NASDAQ:CTXR) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.14). As a group, research analysts expect that Citius Pharmaceuticals Inc will post -0.61 earnings per share for the current year.
In other Citius Pharmaceuticals news, CEO Myron Z. Holubiak bought 558,597 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The stock was bought at an average cost of $0.90 per share, for a total transaction of $502,737.30. Also, major shareholder Leonard L. Mazur bought 2,234,700 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average price of $0.90 per share, with a total value of $2,011,230.00. Insiders own 58.52% of the company’s stock.
An institutional investor recently raised its position in Citius Pharmaceuticals stock. Vanguard Group Inc. boosted its holdings in shares of Citius Pharmaceuticals Inc (NASDAQ:CTXR) by 308.3% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 453,156 shares of the company’s stock after purchasing an additional 342,180 shares during the period. Vanguard Group Inc. owned about 2.05% of Citius Pharmaceuticals worth $444,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 2.83% of the stock is owned by institutional investors.
Citius Pharmaceuticals Company Profile (NASDAQ:CTXR)
Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.
Read More: 12b-1 Fees
Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.